Works matching AU Abrams, Ken

Results: 9

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study.

Published in:

Rheumatology & Therapy, 2019, v. 6, n. 3, p. 393, doi. 10.1007/s40744-019-0163-5

By:

Kivitz, Alan J.;
Nash, Peter;
Tahir, Hasan;
Everding, Andrea;
Mann, Heřman;
Kaszuba, Andrzej;
Pellet, Pascale;
Widmer, Albert;
Pricop, Luminita;
Abrams, Ken

Publication type:

Article

Cognitive behavioral treatment of comorbid anxiety disorder in alcoholism treatment patients: Presentation of a prototype program and future directions.

Published in:

Journal of Mental Health, 2006, v. 15, n. 6, p. 697, doi. 10.1080/09638230600998946

By:

Kushner, Matt G.;
Donahue, Christopher;
Sletten, Sandra;
Thuras, Paul;
Abrams, Ken;
Peterson, Jill;
Frye, Brenda

Publication type:

Article

Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.

Published in:

Arthritis & Rheumatology, 2016, v. 68, n. 1, p. 218, doi. 10.1002/art.39407

By:

Grom, Alexei A.;
Ilowite, Norman T.;
Pascual, Virginia;
Brunner, Hermine I.;
Martini, Alberto;
Lovell, Daniel;
Ruperto, Nicolino;
Leon, Karolynn;
Lheritier, Karine;
Abrams, Ken;
Cuttica, Ruben;
Emminger, Wolfgang;
Goffin, Laurence;
Joos, Rik;
Lauwerys, Bernard;
Wouters, Carine;
Hilário, Maria Odete Esteves;
de Oliveira, Sheila Knupp Feitosa;
Len, Claudio;
Radominski, Sebastiao

Publication type:

Article

Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis.

Published in:

Journal of Dermatological Treatment, 2006, v. 17, n. 3, p. 143, doi. 10.1080/09546630600647297

By:

Siegfried, Elaine;
Korman, Neil;
Molina, Carmen;
Kianifard, Farid;
Abrams, Ken

Publication type:

Article

A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.

Published in:

Journal of Dermatological Treatment, 2005, v. 16, n. 3, p. 142, doi. 10.1080/09546630510033159

By:

Ling, Mark;
Gottlieb, Alice;
Pariser, David;
Caro, Ivan;
Stewart, Daniel;
Scott, Graham;
Abrams, Ken

Publication type:

Article

Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.

Published in:

Journal of Clinical Pharmacology, 2016, v. 56, n. 12, p. 1516, doi. 10.1002/jcph.754

By:

Sun, Haiying;
Van, Linh M.;
Floch, David;
Jiang, Xuemin;
Klein, Ulf R.;
Abrams, Ken;
Sunkara, Gangadhar

Publication type:

Article

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study.

Published in:

Arthritis & Rheumatology, 2021, v. 73, n. 2, p. 336, doi. 10.1002/art.41488

By:

Quartier, Pierre;
Alexeeva, Ekaterina;
Constantin, Tamàs;
Chasnyk, Vyacheslav;
Wulffraat, Nico;
Palmblad, Karin;
Wouters, Carine;
I. Brunner, Hermine;
Marzan, Katherine;
Schneider, Rayfel;
Horneff, Gerd;
Martini, Alberto;
Anton, Jordi;
Wei, Xiaoling;
Slade, Alan;
Ruperto, Nicolino;
Abrams, Ken;
Emminger, W.;
Ulbrich, A.;
Fodor, S.

Publication type:

Article

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.

Published in:

Kidney International, 2008, v. 74, n. 5, p. 641, doi. 10.1038/ki.2008.193

By:

Boonen, Steven;
Sellmeyer, Deborah E.;
Lippuner, Kurt;
Orlov-Morozov, Alexander;
Abrams, Ken;
Mesenbrink, Peter;
Eriksen, Erik F.;
Miller, Paul D.

Publication type:

Article

257 Secukinumab demonstrates a consistent safety profile with up to 5 years' treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses.

Published in:

2019

By:

McInnes, Iain B;
Mease, Philip J;
Reich, Kristian;
Nash, Peter;
Widmer, Albert;
Abrams, Ken;
Pricop, Luminita;
Fox, Todd

Publication type:

Abstract